Scott Kellogg Email & Phone Number

Massachusetts

Co-founded by Bob Langer and Gio Traverso at MIT, GEM-Biosciences promises to revolutionize wound care, inflammation, and regeneration treatments with its breakthrough Gas Entrapped Materials (GEM) technology, designed to administer therapeutic gases directly, safely, and effectively to the affected areas. Our first product promises to be a game-changing.

Foxborough, Massachusetts, United States

• Recruited to lead vision, strategy, growth, and development of start-up biotech that enables first-generation products providing oral delivery of biologics and genetics, which is transformative to treating intractable.
• Successfully hit every milestone since starting the company, from product development, sourcing drugs, preclinical work and human trials in Australia, taking drugs from development to human trials in two years
• Overseeing seven executives; recruited Head of Clinical Affairs, Head of Engineering, Head of Regulatory, and two junior engineers
• Secured $8.5M in funding, tapping into a vast VC (Venture Capitalist) network, supporting the development of first-generation product and human trials within two years; negotiated license from MIT
• Currently raising $15M for subsequent round funding

Puretech Health - Boston MA

• Recruited to develop a company that launched a new industry with the world’s first therapeutic software algorithm as a mobile app to help children with ADHD. The first cleared indication was for the treatment of.
• Built infrastructure to develop software as a medical device, managed clinical operations, regulatory, and quality functions to ensure product success
• Led design and execution of large randomized, controlled, blinded clinical trials, resulting in successful submission, FDA clearance of de novo application for pediatric ADHD; company received CE certification (June.
• Executed a regulatory strategy that brought FDA Pediatric Device Consortia, Ombudsman, and senior leadership to the table
• Managed research collaborations with pharma partners: Shionogi Pharmaceuticals (Japan), Shire (early investors with first $500K in – now Takeda), and Pfizer research collaboration assessing tech for predicting amyloid.
• Responsible for a $5M annual budget, leading nine parallel clinical programs with a 10-member team of quality, regulatory, and clinical operations leadership; grew the company from 3 to 80 associates, raising $120M in.

Puretech Health - Boston MA

• Recruited to develop a company that created the first dermal de novo stem cell creation technology. Managed R&D, device development, clinical operations, IP, and regulatory functions. The in situ stem cell formation.
• Managed $3M annual budget, responsible for 8-member team of scientists, drug developers, and engineers
• Guided R&D, Clinical Operations, regulatory functions, managing the company’s lab, budgets, and portfolio
• Led design and development of two human device trials and one drug-device combination OUS (Charité Hospital) trial; for the first time, these trials demonstrated the creation of neogenic hair follicles
• Built functional teams and advisory boards, secured early funding, and managed the IP portfolio
• Helped the company raise ~$17M and optimize devices and topical formulations invented to achieve continued and increased clinical results

Providence, Rhode Island, United States

• Converted large cart-based laboratory devices into wearable devices with high-value disposal components. The company focused on developing a novel neuro-stimulation technology, which theorized it would accelerate.
• Established the start-up team and drove redevelopment of a large-cart-based lab device footprint into a small, wearable device with a low-profile, piezo-based mechanical stimulator incorporated into a disposable.
• Managed device development, quality management, and regulatory
• Oversaw the external network of the product development team and Stryker Medical collaboration

Cambridge, Massachusetts, United States

• Hired as a member of the start-up team; led the development of SonoPrep, a company that makes a handheld device that generates ultrasound acoustic cavitation to achieve enhanced skin permeability.
• Led 12 direct reports composed of scientists and engineers, led the internal R&D team, and managed a $4M budget while expanding the IP portfolio. Sontra went public (2002), then merged with Echo Therapeutics (2007)
• Successfully raised $11M before the IPO
• Developed SonoPrep, a handheld device generating ultrasound acoustic cavitation to enhance skin permeability. This invention also included a novel feedback mechanism to control the dosage to achieve consistent.
• Led development of SoniCate Transdermal Drug Delivery System, which the first commercial indication was for painless pediatric canulation
• Led development of the Symphony Transdermal Continuous Glucose Monitoring System, including the proprietary highly sensitive sensor incorporated into a half-dollar-sized wearable transmitter (collaborated with Bayer.

Norwell, Massachusetts, United States

• Rebooted an extensive surgical program that had fallen behind schedule and was over budget. Steered a large multi-discipline team to develop the Contour Genesis system, an ultrasound generator, a handpiece with a.
• Managed a $15M budget, responsible for the surgical device development functions
• Directed a large internal 40-member team of electrical, software, mechanical, quality, and manufacturability engineers while supporting regulatory and clinical functions
• Interfaced with world-renowned plastic surgeons to optimize and refine the design
• Piloted team in completing the development of the Contour Genesis system in 14 months, setting a company record in vision to launch; the IDE clinical evaluation and clearance resulted in a highly successful commercial.
• Led successful transfer to manufacturing and redirected regulatory strategy away from PMA to 510(k), resulting in significant manufacturing and compliance savings

Smithfield RI / Cincinnati OH

• Leader in inventing and developing the Harmonic Scalpel, revolutionizing the emerging laparoscopic surgical field. The safety and efficacy profile of the technology-enabled multiple new procedures previously without a.
• Advanced capabilities of the surgical device development function, which today generates $1B+ annually
• Developed the international technical service training and executed this program globally
• Instrumental in the business integration after UltraCision was sold to J&J EES for $85M

Master Of Business Administration - Mba, Business, Finance

Master Of Science - Ms, Accounting And Finance

Bs, Engineering